Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for InMed Pharmaceuticals (INM) over the last 3 years, with Q4 2025 value amounting to $4199.0.

  • InMed Pharmaceuticals' Change in Acquisitions & Divestments rose 5679.61% to $4199.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $43424.0, marking a year-over-year decrease of 300.0%. This contributed to the annual value of $42270.0 for FY2025, which is 44.67% up from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Change in Acquisitions & Divestments is $4199.0, which was up 5679.61% from $20957.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Change in Acquisitions & Divestments ranged from a high of $21324.0 in Q3 2024 and a low of -$431.0 during Q2 2024
  • Its 3-year average for Change in Acquisitions & Divestments is $12167.6, with a median of $16037.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in InMed Pharmaceuticals' Change in Acquisitions & Divestments was 61763.34% (2025), while the steepest drop was 2433.95% (2025).
  • Quarter analysis of 3 years shows InMed Pharmaceuticals' Change in Acquisitions & Divestments stood at $21317.0 in 2023, then tumbled by 87.44% to $2678.0 in 2024, then skyrocketed by 56.8% to $4199.0 in 2025.
  • Its last three reported values are $4199.0 in Q4 2025, $20957.0 for Q3 2025, and $2231.0 during Q2 2025.